Pregabalin versus SSRIs and SNRIs in benzodiazepine-refractory outpatients with generalized anxiety disorder: A post hoc cost-effectiveness analysis in usual medical practice in Spain

ClinicoEconomics and Outcomes Research

Volumn 4, Issue 1, 2012, Pages 157-168

  De Salas Cansado, Marina ^a   Olivares, José M ^b   Álvarez, Enrique ^c   Carrasco, Jose L ^d   Barrueta, Andoni ^e   Rejas, Javier ^e  

^a Trial Form Support Spain ^*  (Spain)

^b HOSPITAL DO MEIXOEIRO   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e PFIZER INC   (United States)

Author keywords

Benzodiazepine refractory patients; Cost effectiveness; Generalized anxiety disorder; Pregabalin; Quality adjusted life years

Indexed keywords

BENZODIAZEPINE; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; MIRTAZAPINE; PAROXETINE; PREGABALIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ADULT; ANXIETY; ARTICLE; BOOTSTRAPPING; CLINICAL GLOBAL IMPRESSION SCALE; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; DSM-IV; FEMALE; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; NATIONAL HEALTH SERVICE; OUTPATIENT; OUTPATIENT CARE; POST HOC ANALYSIS; PROSPECTIVE STUDY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SENSITIVITY ANALYSIS; SPAIN; SYMPTOMATOLOGY;

EID: 84930484524     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S31102     Document Type: Article

References (48)

1. Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ, WFSBP task force on treatment guidelines for anxiety obsessive-compulsive post-traumatic stress disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders-first revision. World J Biol Psychiatry. 2009;4:248-312.
2. Judd LL, Kessler RC, Paulus MP, Zeller PV, Wittchen HU, Kunovac JL. Comorbidity as a fundamental feature of generalized anxiety disorders: results from the National Comorbidity Study (NCS). Acta Psychiatr Scand Suppl. 1998;393:6-11.
3. Ballenger JC, Davidson JR, Lecrubier Y, et al. Consensus statement of generalized anxiety disorder from the international consensus group on depression and anxiety. J Clin Psychiatry. 2001;62 Suppl 11:53-58.
4. Wittchen HU, Kessler RC, Beesdo K, Krause P, Hofler M, Hoyer J. Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry. 2002;63 Suppl 8:24-34.
5. Alonso J, Angermeyer MC, Bernert S, et al. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl. 2004;Suppl 420:21-27.
6. Kessler RC, Wittchen HU. Patterns and correlates of generalized anxiety disorder in community samples. J Clin Psychiatry. 2002;63 Suppl 8:4-10.
7. Chocron Bentata L, Vilalta Franch J, Legazpi Rodriguez I, Auquer K, Franch L. Prevalence of psychopathology at a primary care center. Aten Primaria. 1995;16:586-590. Spanish.
8. Caballero L, Bobes J, Vilardaga I, Rejas J. Clinical prevalence and reason for visit of patients with generalized anxiety disorder seen in the psychiatry out-patient clinics in Spain. Results of the LIGANDO study. Actas Esp Psiquiatr. 2009;37:17-20. Spanish.
9. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:593-602.
10. Lieb R, Becker E, Altamura C. The epidemiology of generalized anxiety disorder in Europe. Eur Neuropsychopharmacol. 2005;15:445-452.
11. Katzman MA. Current considerations in the treatment of generalized anxiety disorder. CNS Drugs. 2009;23:103-120.
12. Andlin-Sobocki P, Wittchen HU. Cost of anxiety disorders in Europe. Eur J Neurol. 2005;12 Suppl 1:39-44.
13. McLaughlin TP, Khandker RK, Kruzikas DT, Tummala R. Overlap of anxiety and depression in a managed care population: prevalence and association with resource utilization. J Clin Psychiatry. 2006;67: 1187-1193.
14. Wittchen HU. Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety. 2002;16:162-171.
15. Pollack MH. Refractory generalized anxiety disorder. J Clin Psychiatry. 2009;70 Suppl 2:32-38.
16. Davidson JR. First-line pharmacotherapy approaches for generalized anxiety disorder. J Clin Psychiatry. 2009;70 Suppl 2:25-31.
17. Rickels K, Downing R, Schweizer E, Hassman H. Antidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry. 1993;50:884-895.
18. Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem. 1996;271:5768-5776.
19. Dooley DJ, Donovan CM, Pugsley TA. Stimulus-dependent modulation of [(3)H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J Pharmacol Exp Ther. 2000;295:1086-1093.
20. Maneuf YP, Hughes J, McKnight AT. Gabapentin inhibits the substance P-facilitated K(+)-evoked release of [(3)H]glutamate from rat caudal trigeminal nucleus slices. Pain. 2001;93:91-96.
21. Fink K, Dooley DJ, Meder WP, et al. Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology. 2002;42:229-236.
22. Konnopka A, Leichsenring F, Leibing E, König HH. Cost-of-illness studies and cost-effectiveness analyses in anxiety disorders: a systematic review. J Affect Disord. 2009;114:14-31.
23. Vera-Llonch M, Dukes E, Rejas J, Sofrygin O, Mychaskiw M, Oster G. Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective. Eur J Health Econ. 2010;11:35-44.
24. Álvarez E, Carrasco JL, Olivares JM, et al. Broadening of generalized anxiety disorders definition does not affect the response to therapy: findings from the ADAN study. Eur Psychiatry. 2010;25 Suppl 1:Abstract PW01-50.
25. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
26. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50-55.
27. Lobo A, Chamorro L, Luque A, Dal-Ré R, Badía X, Baró E. Validación de las versiones en español de la Montgomery-Asberg Depression Scale y la Hamilton Anxiety Rating Scale para la evaluación de la depresión y de la ansiedad. Med Clin (Barc). 2002;118:493-499. Spanish.
28. Guy W. ECDEU Assessment Manual for Psychopharmacology Revised. Rockville, MD: US Department of Health Education, and Welfare, Psychopharmacology Research Branch; 1976.
29. EuroQoL Group. EuroQoL-a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199-208.
30. Badía X, Roset M, Montserrat S, Herdman M, Segura A. The Spanish version of EuroQoL: a description and its applications. European Quality of Life scale. Med Clin (Barc). 1999;112 Suppl 1:79-85. Spanish.
31. Sacristán JA, Oliva J, Del Llano J, Prieto L, Pinto JL. Qué es una tecnología sanitaria eficiente en España? Gac Sanit. 2002;4:334-343. Spanish.
32. Catálogo del Consejo General de Colegios Farmacéuticos de España, BOT base de datos del medicamento 2008.
33. Oblikue, 2008. eSALUD. Base de datos de costes sanitarios. In: Social, S.C.d.E.e.E.d.l.S.y.P. editor. Soikos, Barcelona.
34. INE. [http://www.ine.es] Spain 2008. Accessed Aug 2008.
35. Revicki D, Brandenburg M, Matza LS, et al. Relationship between anxiety severity and health utility index scores in generalized anxiety disorder. Presented at the Collegium of Internationale Neuro-Psycharmacologicum, Chicago, IL; July 9-13, 2006.
36. Morlock R, Shah H, Feltner D, Brandenburg N, Matza LS, Revicki D. Estimation of health-state utilities for patients with generalized anxiety disorder. Presented at the Collegium of Internationale Neuro-Psycharmacologicum, Chicago, IL; July 9-13, 2006.
37. Bastida JL, Oliva J, Antoñanzas F, et al. A proposed guideline for economic evaluation of health technologies. Gac Sanit. 2010;24:154-170. Spanish.
38. Gao K, Sheehan DV, Calabrese JR. Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders. Expert Rev Neurother. 2009;9:1147-1158.
39. Heuzenröeder L, Donnelly M, Haby MM, et al. Cost-effectiveness of psychological and pharmacological interventions for generalized anxiety disorder and panic disorder. Psychiatry. 2004;38:602-612.
40. Issakidis C, Sanderson K, Corry J, Andrews G, Lapsley H. Modelling the population cost-effectiveness of current and evidence-based optimal treatment for anxiety disorders. Psychol. Med. 2004;34:19-35.
41. Guest JF, Russ J, Lenox-Smith A. Cost-effectiveness of venlafaxine XL compared with diazepam in the treatment of generalized anxiety disorder in the United Kingdom. Eur J Health Econ. 2005;6:136-145.
42. Jørgensen TR, Stein DJ, Despiegel N, Drost PB, Hemels ME, Baldwin DS. Cost-effectiveness analysis of escitalopram compared with paroxetine in treatment of generalized anxiety disorder in the United Kingdom. Ann Pharmacother. 2006;40:1752-1758.
43. Baldinetti F, Bandelow B, Kasper S, et al. Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. Int Clin Psychopharmacol. 2009;24:87-96.
44. Weinstein MC, O'Brien B, Hornberger J, etal; ISPOR Task Force on Good Research Practices. Principles of good practice for decision analytic modelling in health care evaluation: report of the ISPOR Task Force on good research practices-modeling studies. Value Health. 2003;6:9-17.
45. National Institute for Clinical Excellence. Guide to the Methods of Technology Appraisal. London, UK: National Institute for Clinical Excellence; 2004.
46. Pollack MH, Otto MW, Roy-Byrne PP, et al. Novel treatment approaches for refractory anxiety disorders. Depress Anxiety. 2008;25:467-476.
47. Simon NM, Connor KM, LeBeau RT, et al. Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. Psychopharmacology (Berl). 2008;197:675-681.
48. Pollack MH, Simon NM, Zalta AK, et al. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry. 2006;59:211-215.